138 related articles for article (PubMed ID: 38305134)
21. Usefulness of cardiac magnetic resonance for early detection of cancer therapeutics-related cardiac dysfunction in breast cancer patients.
Terui Y; Sugimura K; Ota H; Tada H; Nochioka K; Sato H; Katsuta Y; Fujiwara J; Harada-Shoji N; Sato-Tadano A; Morita Y; Sun W; Higuchi S; Tatebe S; Fukui S; Miyamichi-Yamamoto S; Suzuki H; Yaoita N; Kikuchi N; Sakota M; Miyata S; Sakata Y; Ishida T; Takase K; Yasuda S; Shimokawa H
Int J Cardiol; 2023 Jan; 371():472-479. PubMed ID: 36115441
[TBL] [Abstract][Full Text] [Related]
22. Left atrial longitudinal strain as a predictor of Cancer therapeutics-related cardiac dysfunction in patients with breast Cancer.
Park H; Kim KH; Kim HY; Cho JY; Yoon HJ; Hong YJ; Park HW; Kim JH; Ahn Y; Jeong MH; Cho JG
Cardiovasc Ultrasound; 2020 Jul; 18(1):28. PubMed ID: 32693802
[TBL] [Abstract][Full Text] [Related]
23. Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients.
De Iuliis F; Salerno G; Taglieri L; De Biase L; Lanza R; Cardelli P; Scarpa S
Tumour Biol; 2016 Mar; 37(3):3379-87. PubMed ID: 26449821
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and Prognostic Value of Myocardial Work Indices for Identification of Cancer Therapy-Related Cardiotoxicity.
Calvillo-Argüelles O; Thampinathan B; Somerset E; Shalmon T; Amir E; Steve Fan CP; Moon S; Abdel-Qadir H; Thevakumaran Y; Day J; Woo A; Wintersperger BJ; Marwick TH; Thavendiranathan P
JACC Cardiovasc Imaging; 2022 Aug; 15(8):1361-1376. PubMed ID: 35926895
[TBL] [Abstract][Full Text] [Related]
25. The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy.
Laufer-Perl M; Arnold JH; Mor L; Amrami N; Derakhshesh M; Moshkovits Y; Sadeh B; Arbel Y; Topilsky Y; Rozenbaum Z
Clin Res Cardiol; 2020 Feb; 109(2):255-262. PubMed ID: 31214777
[TBL] [Abstract][Full Text] [Related]
26. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
[TBL] [Abstract][Full Text] [Related]
27. Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial.
Negishi T; Thavendiranathan P; Negishi K; Marwick TH;
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1098-1105. PubMed ID: 29909105
[TBL] [Abstract][Full Text] [Related]
28. Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity: A Three Dimentional Echocardiography Study.
Mohamed AL; El-Abd AA; Mohamed HG; Noufal AM; Hennawy BS
Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102130. PubMed ID: 37858847
[TBL] [Abstract][Full Text] [Related]
29. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
[TBL] [Abstract][Full Text] [Related]
30. Artificial intelligence-enabled prediction of chemotherapy-induced cardiotoxicity from baseline electrocardiograms.
Yagi R; Goto S; Himeno Y; Katsumata Y; Hashimoto M; MacRae CA; Deo RC
Nat Commun; 2024 Mar; 15(1):2536. PubMed ID: 38514629
[TBL] [Abstract][Full Text] [Related]
31. Can global longitudinal strain (GLS) with magnetic resonance prognosticate early cancer therapy-related cardiac dysfunction (CTRCD) in breast cancer patients, a prospective study?
Kar J; Cohen MV; McQuiston SA; Malozzi CM
Magn Reson Imaging; 2023 Apr; 97():68-81. PubMed ID: 36581216
[TBL] [Abstract][Full Text] [Related]
32. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
Matos E; Jug B; Blagus R; Zakotnik B
Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
[TBL] [Abstract][Full Text] [Related]
33. Atrial Strain Assessment for the Early Detection of Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer Women (The STRANO STUDY: Atrial Strain in Cardio-Oncology).
Di Lisi D; Moreo A; Casavecchia G; Cadeddu Dessalvi C; Bergamini C; Zito C; Madaudo C; Madonna R; Cameli M; Novo G
J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002739
[TBL] [Abstract][Full Text] [Related]
34. Nomogram for Predicting Risk of Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Yu AF; Lin IH; Jorgensen J; Copeland-Halperin R; Feldman S; Ibtida I; Assefa A; Johnson MN; Dang CT; Liu JE; Steingart RM
J Am Heart Assoc; 2023 Oct; 12(19):e029465. PubMed ID: 37750581
[TBL] [Abstract][Full Text] [Related]
35. Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study.
Thavendiranathan P; Abdel-Qadir H; Fischer HD; Camacho X; Amir E; Austin PC; Lee DS
J Clin Oncol; 2016 Jul; 34(19):2239-46. PubMed ID: 27091709
[TBL] [Abstract][Full Text] [Related]
36. Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer.
Finkelman BS; Putt M; Wang T; Wang L; Narayan H; Domchek S; DeMichele A; Fox K; Matro J; Shah P; Clark A; Bradbury A; Narayan V; Carver JR; Tang WHW; Ky B
J Am Coll Cardiol; 2017 Jul; 70(2):152-162. PubMed ID: 28683962
[TBL] [Abstract][Full Text] [Related]
37. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).
Čelutkienė J; Pudil R; López-Fernández T; Grapsa J; Nihoyannopoulos P; Bergler-Klein J; Cohen-Solal A; Farmakis D; Tocchetti CG; von Haehling S; Barberis V; Flachskampf FA; Čeponienė I; Haegler-Laube E; Suter T; Lapinskas T; Prasad S; de Boer RA; Wechalekar K; Anker MS; Iakobishvili Z; Bucciarelli-Ducci C; Schulz-Menger J; Cosyns B; Gaemperli O; Belenkov Y; Hulot JS; Galderisi M; Lancellotti P; Bax J; Marwick TH; Chioncel O; Jaarsma T; Mullens W; Piepoli M; Thum T; Heymans S; Mueller C; Moura B; Ruschitzka F; Zamorano JL; Rosano G; Coats AJS; Asteggiano R; Seferovic P; Edvardsen T; Lyon AR
Eur J Heart Fail; 2020 Sep; 22(9):1504-1524. PubMed ID: 32621569
[TBL] [Abstract][Full Text] [Related]
38. Monocyte-to-lymphocyte ratio as predictor of cancer therapy-related cardiotoxicity in patients with breast cancer: a pilot cohort study.
Pivatto Júnior F; Santos ÂBS; Englert EF; Mazzutti G; Costa GOM; Saffi MAL; Liedke PER; Fritsch VH; Biolo A
Breast Cancer Res Treat; 2023 Aug; 200(3):355-362. PubMed ID: 37273150
[TBL] [Abstract][Full Text] [Related]
39. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
[TBL] [Abstract][Full Text] [Related]
40. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
